Sek Kathiresan, MD
CEO, Verve Therapeutics
From reading the genome for risk to rewriting for cardiovascular health
Coronary heart disease is a heritable, common, complex disease and the leading cause of death in the world. Dr. Kathiresan will review progress in our understanding of the inherited basis for risk as well resistance to coronary heart disease. He will then turn to approaches to “rewrite” the genome using gene editing to treat coronary heart disease.
